Danske Bank’s Aptevo Therapeutics APVO Stock Holding History

Danske Bank’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4	Hold	1	–	–	﹤0.01%	1111
2025 Q4	$9	Buy	+1	New	+$24	﹤0.01%	1482
2025 Q3	–	Hold	0	–	–	–	1477
2025 Q2	–	Hold	0	–	–	–	1485
2025 Q1	–	Hold	0	–	-$4	–	1383
2024 Q4	–	Hold	0	–	–	–	1360

Other funds holding APVO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Danske Bank's APVO Position: Q1 2026 in Review

Danske Bank held its Aptevo Therapeutics (APVO) position steady in Q1 2026 at 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #1111.

Danske Bank first reported a position in APVO in Q4 2025 and has held it in 2 quarters since. The position peaked at $9 in Q4 2025. 9 funds tracked by Wall St. Rank hold APVO as of Q1 2026.

Danske Bank held 1 share of Aptevo Therapeutics worth $4 as of Q1 2026.
Danske Bank left its Aptevo Therapeutics share count unchanged in Q1 2026.
Aptevo Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1111 holding.
Danske Bank first reported a position in Aptevo Therapeutics in Q4 2025 and has held it in 2 quarters since.
Danske Bank's Aptevo Therapeutics position peaked at $9 in Q4 2025.
9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.